Transthyretin deposition in articular cartilage: A novel mechanism in the pathogenesis of osteoarthritis

Arthritis and Rheumatology

Volumn 67, Issue 8, 2015, Pages 2097-2107

  Akasaki, Yukio ^a   Reixach, Natàlia ^a   Matsuzaki, Tokio ^a   Alvarez Garcia, Oscar ^a   Olmer, Merissa ^a   Iwamoto, Yukihide ^b   Buxbaum, Joel N ^a   Lotz, Martin K ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID; CONGO RED; MITOGEN ACTIVATED PROTEIN KINASE P38; PREALBUMIN; RECOMBINANT PROTEIN; RESVERATROL; TOLL LIKE RECEPTOR 4; AMYLOID PROTEIN; IMMUNOGLOBULIN RECEPTOR; MESSENGER RNA; TLR4 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; ARTICULAR CARTILAGE; BIREFRINGENCE; CARTILAGE CELL; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY ASSAY; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KNEE MENISCUS; MALE; METABOLIC ACTIVITY ASSAY; OSTEOARTHRITIS; PRIORITY JOURNAL; SYNOVIAL FLUID; WESTERN BLOTTING; CELL CULTURE; DRUG EFFECTS; GENETICS; KNEE OSTEOARTHRITIS; METABOLISM; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; AGED; AGED, 80 AND OVER; AMYLOIDOGENIC PROTEINS; BLOTTING, WESTERN; CARTILAGE, ARTICULAR; CELLS, CULTURED; CHONDROCYTES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PREALBUMIN; RECEPTORS, IMMUNOLOGIC; RECOMBINANT PROTEINS; RNA, MESSENGER; SYNOVIAL FLUID; TOLL-LIKE RECEPTOR 4; YOUNG ADULT;

EID: 84938151998     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39178     Document Type: Article

References (69)

1. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al., for the National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part II. Arthritis Rheum 2008; 58: 26-35.
2. Buxbaum JN., The systemic amyloidoses. Curr Opin Rheumatol 2004; 16: 67-75.
3. Loeser RF, Goldring SR, Scanzello CR, Goldring MB., Osteoarthritis: a disease of the joint as an organ [review]. Arthritis Rheum 2012; 64: 1697-707.
4. Lotz M, Loeser RF., Effects of aging on articular cartilage homeostasis. Bone 2012; 51: 241-8.
5. Powers ET, Morimoto RI, Dillin A, Kelly JW, Balch WE., Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem 2009; 78: 959-91.
6. 2-microglobulin on articular chondrocytes. Osteoarthritis Cartilage 2008; 16: 1336-42.
7. Elsaman AM, Radwan AR, Akmatov MK, Della Beffa C, Walker A, Mayer CT, et al., Amyloid arthropathy associated with multiple myeloma: a systematic analysis of 101 reported cases. Semin Arthritis Rheum 2013; 43: 405-12.
8. Reinke AA, Gestwicki JE., Insight into amyloid structure using chemical probes. Chem Biol Drug Des 2011; 77: 399-411.
9. Bywaters EG, Dorling J., Amyloid deposits in articular cartilage. Ann Rheum Dis 1970; 29: 294-306.
10. Egan MS, Goldenberg DL, Cohen AS, Segal D., The association of amyloid deposits and osteoarthritis. Arthritis Rheum 1982; 25: 204-8.
11. Mitrovic DR, Stankovic A, Quintero M, Ryckewaert A., Amyloid deposits in human knee and hip joints. Rheumatol Int 1985; 5: 83-9.
12. Ladefoged C., Amyloid deposits in the knee joint at autopsy. Ann Rheum Dis 1986; 45: 668-72.
13. Athanasou NA, Sallie B., Localized deposition of amyloid in articular cartilage. Histopathology 1992; 20: 41-6.
14. Niggemeyer O, Steinhagen J, Deuretzbacher G, Zustin J, Ruther W., Amyloid deposition in osteoarthritis of the hip. Arch Orthop Trauma Surg 2011; 131: 637-43.
15. Sohn DH, Sokolove J, Sharpe O, Erhart JC, Chandra PE, Lahey LJ, et al., Plasma proteins present in osteoarthritic synovial fluid can stimulate cytokine production via Toll-like receptor 4. Arthritis Res Ther 2012; 14: R7.
16. Cornwell GG III, Sletten K, Johansson B, Westermark P., Evidence that the amyloid fibril protein in senile systemic amyloidosis is derived from normal prealbumin. Biochem Biophys Res Commun 1988; 154: 648-53.
17. Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, et al., Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in α2-macroglobulin and tau: a population-based autopsy study. Ann Med 2008; 40: 232-9.
18. Ando Y, Nakamura M, Araki S., Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 2005; 62: 1057-62.
19. Benson MD, Kluve-Beckerman B, Liepnieks JJ, Murrell JR, Hanes D, Uemichi T., Metabolism of amyloid proteins. Ciba Found Symp 1996; 199: 104-13.
20. Hurshman AR, White JT, Powers ET, Kelly JW., Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. Biochemistry 2004; 43: 7365-81.
21. Akasaki Y, Hasegawa A, Saito M, Asahara H, Iwamoto Y, Lotz MK., Dysregulated FOXO transcription factors in articular cartilage in aging and osteoarthritis. Osteoarthritis Cartilage 2014; 22: 162-70.
22. Bourgault S, Choi S, Buxbaum JN, Kelly JW, Price JL, Reixach N., Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs. Biochem Biophys Res Commun 2011; 410: 707-13.
23. Carames B, Kiosses WB, Akasaki Y, Brinson DC, Eap W, Koziol J, et al., Glucosamine activates autophagy in vitro and in vivo. Arthritis Rheum 2013; 65: 1843-52.
24. Rappley I, Monteiro C, Novais M, Baranczak A, Solis G, Wiseman RL, et al., Quantification of transthyretin kinetic stability in human plasma using subunit exchange. Biochemistry 2014; 53: 1993-2006.
25. Anoopkumar-Dukie S, Carey JB, Conere T, O'Sullivan E, van Pelt FN, Allshire A., Resazurin assay of radiation response in cultured cells. Br J Radiol 2005; 78: 945-7.
26. O'Brien J, Wilson I, Orton T, Pognan F., Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 2000; 267: 5421-6.
27. Felding P, Fex G., Cellular origin of prealbumin in the rat. Biochim Biophys Acta 1982; 716: 446-9.
28. Dickson PW, Howlett GJ, Schreiber G., Rat transthyretin (prealbumin): molecular cloning, nucleotide sequence, and gene expression in liver and brain. J Biol Chem 1985; 260: 8214-9.
29. Teng MH, Yin JY, Vidal R, Ghiso J, Kumar A, Rabenou R, et al., Amyloid and nonfibrillar deposits in mice transgenic for wild-type human transthyretin: a possible model for senile systemic amyloidosis. Lab Invest 2001; 81: 385-96.
30. Niggemeyer O, Steinhagen J, Zustin J, Ruther W., The value of routine histopathology during hip arthroplasty in patients with degenerative and inflammatory arthritis. Hip Int 2011; 21: 98-106.
31. Gu YJ, Ge P, Mu Y, Lu JH, Zheng F, Sun XG., Clinical and laboratory characteristics of patients having amyloidogenic transthyretin deposition in osteoarthritic knee joints. J Zhejiang Univ Sci B 2014; 15: 92-9.
32. Takanashi T, Matsuda M, Yazaki M, Yamazaki H, Nawata M, Katagiri Y, et al., Synovial deposition of wild-type transthyretin-derived amyloid in knee joint osteoarthritis patients. Amyloid 2013; 20: 151-5.
33. Sekijima Y, Uchiyama S, Tojo K, Sano K, Shimizu Y, Imaeda T, et al., High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly. Hum Pathol 2011; 42: 1785-91.
34. Takei Y, Hattori T, Gono T, Tokuda T, Saitoh S, Hoshii Y, et al., Senile systemic amyloidosis presenting as bilateral carpal tunnel syndrome. Amyloid 2002; 9: 252-5.
35. Takei Y, Hattori T, Tokuda T, Matsuda M, Saitoh S, Hoshii Y, et al., Senile systemic amyloidosis starting as bilateral carpal and left ulnar tunnel syndrome. Intern Med 2003; 42: 1050-1.
36. Hollander AP, Pidoux I, Reiner A, Rorabeck C, Bourne R, Poole AR., Damage to type II collagen in aging and osteoarthritis starts at the articular surface, originates around chondrocytes, and extends into the cartilage with progressive degeneration. J Clin Invest 1995; 96: 2859-69.
37. Kelly JW., The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr Opin Struct Biol 1998; 8: 101-6.
38. Quintas A, Vaz DC, Cardoso I, Saraiva MJ, Brito RM., Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J Biol Chem 2001; 276: 27207-13.
39. Zhao L, Buxbaum JN, Reixach N., Age-related oxidative modifications of transthyretin modulate its amyloidogenicity. Biochemistry 2013; 52: 1913-26.
40. Saito S, Ando Y, Nakamura M, Ueda M, Kim J, Ishima Y, et al., Effect of nitric oxide in amyloid fibril formation on transthyretin-related amyloidosis. Biochemistry 2005; 44: 11122-9.
41. Noborn F, O'Callaghan P, Hermansson E, Zhang X, Ancsin JB, Damas AM, et al., Heparan sulfate/heparin promotes transthyretin fibrillization through selective binding to a basic motif in the protein. Proc Natl Acad Sci U S A 2011; 108: 5584-9.
42. Bourgault S, Solomon JP, Reixach N, Kelly JW., Sulfated glycosaminoglycans accelerate transthyretin amyloidogenesis by quaternary structural conversion. Biochemistry 2011; 50: 1001-15.
43. Bayliss MT, Osborne D, Woodhouse S, Davidson C., Sulfation of chondroitin sulfate in human articular cartilage: the effect of age, topographical position, and zone of cartilage on tissue composition. J Biol Chem 1999; 274: 15892-900.
44. Burkhardt D, Michel BA, Baici A, Kissling R, Theiler R., Comparison of chondroitin sulphate composition of femoral head articular cartilage from patients with femoral neck fractures and osteoarthritis and controls. Rheumatol Int 1995; 14: 235-41.
45. Bank RA, Bayliss MT, Lafeber FP, Maroudas A, Tekoppele JM., Ageing and zonal variation in post-translational modification of collagen in normal human articular cartilage: the age-related increase in non-enzymatic glycation affects biomechanical properties of cartilage. Biochem J 1998; 330: 345-51.
46. Toyama BH, Hetzer MW., Protein homeostasis: live long, won't prosper. Nat Rev Mol Cell Biol 2013; 14: 55-61.
47. Takinami Y, Yoshimatsu S, Uchiumi T, Toyosaki-Maeda T, Morita A, Ishihara T, et al., Identification of potential prognostic markers for knee osteoarthritis by serum proteomic analysis. Biomark Insights 2013; 8: 85-95.
48. Gobezie R, Kho A, Krastins B, Sarracino DA, Thornhill TS, Chase M, et al., High abundance synovial fluid proteome: distinct profiles in health and osteoarthritis. Arthritis Res Ther 2007; 9: R36.
49. Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE., Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003; 10: 160-84.
50. Reixach N, Deechongkit S, Jiang X, Kelly JW, Buxbaum JN., Tissue damage in the amyloidoses: transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci U S A 2004; 101: 2817-22.
51. Sorgjerd K, Klingstedt T, Lindgren M, Kagedal K, Hammarstrom P. Prefibrillar transthyretin oligomers and cold stored native tetrameric transthyretin are cytotoxic in cell culture. Biochem Biophys Res Commun 2008; 377: 1072-8.
52. Jin H, Liang Q, Chen T, Wang X., Resveratrol protects chondrocytes from apoptosis via altering the ultrastructural and biomechanical properties: an AFM study. PLoS One 2014; 9: e91611.
53. Goldring MB, Otero M., Inflammation in osteoarthritis. Curr Opin Rheumatol 2011; 23: 471-8.
54. Sousa MM, Cardoso I, Fernandes R, Guimaraes A, Saraiva MJ., Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am J Pathol 2001; 159: 1993-2000.
55. Sousa MM, Fernandes R, Palha JA, Taboada A, Vieira P, Saraiva MJ., Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55Pro. Am J Pathol 2002; 161: 1935-48.
56. Buxbaum JN, Tagoe C, Gallo G, Walker JR, Kurian S, Salomon DR., Why are some amyloidoses systemic? Does hepatic "chaperoning at a distance" prevent cardiac deposition in a transgenic model of human senile systemic (transthyretin) amyloidosis? FASEB J 2012; 26: 2283-93.
57. Loeser RF, Yammani RR, Carlson CS, Chen H, Cole A, Im HJ, et al., Articular chondrocytes express the receptor for advanced glycation end products: potential role in osteoarthritis. Arthritis Rheum 2005; 52: 2376-85.
58. Yammani RR, Carlson CS, Bresnick AR, Loeser RF., Increase in production of matrix metalloproteinase 13 by human articular chondrocytes due to stimulation with S100A4: role of the receptor for advanced glycation end products. Arthritis Rheum 2006; 54: 2901-11.
59. Steenvoorden MM, Huizinga TW, Verzijl N, Bank RA, Ronday HK, Luning HA, et al., Activation of receptor for advanced glycation end products in osteoarthritis leads to increased stimulation of chondrocytes and synoviocytes. Arthritis Rheum 2006; 54: 253-63.
60. Cecil DL, Johnson K, Rediske J, Lotz M, Schmidt AM, Terkeltaub R., Inflammation-induced chondrocyte hypertrophy is driven by receptor for advanced glycation end products. J Immunol 2005; 175: 8296-302.
61. Sousa MM, Du Yan S, Fernandes R, Guimaraes A, Stern D, Saraiva MJ., Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways. J Neurosci 2001; 21: 7576-86.
62. Monteiro FA, Cardoso I, Sousa MM, Saraiva MJ., In vitro inhibition of transthyretin aggregate-induced cytotoxicity by full and peptide derived forms of the soluble receptor for advanced glycation end products (RAGE). FEBS Lett 2006; 580: 3451-6.
63. Chen YJ, Sheu ML, Tsai KS, Yang RS, Liu SH., Advanced glycation end products induce peroxisome proliferator-activated receptor γ down-regulation-related inflammatory signals in human chondrocytes via Toll-like receptor-4 and receptor for advanced glycation end products. PLoS One 2013; 8: e66611.
64. Schelbergen RF, Blom AB, van den Bosch MH, Sloetjes A, Abdollahi-Roodsaz S, Schreurs BW, et al., Alarmins S100A8 and S100A9 elicit a catabolic effect in human osteoarthritic chondrocytes that is dependent on Toll-like receptor 4. Arthritis Rheum 2012; 64: 1477-87.
65. Campo GM, Avenoso A, Campo S, D'Ascola A, Nastasi G, Calatroni A., Small hyaluronan oligosaccharides induce inflammation by engaging both Toll-like-4 and CD44 receptors in human chondrocytes. Biochem Pharmacol 2010; 80: 480-90.
66. Hongo M, Kono J, Yamada H, Misawa T, Tanaka M, Nakatsuka T, et al., Doppler echocardiographic assessments of left ventricular diastolic filling in patients with amyloid heart disease. J Cardiol 1991; 21: 391-401.
67. Penchala SC, Connelly S, Wang Y, Park MS, Zhao L, Baranczak A, et al., AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc Natl Acad Sci U S A 2013; 110: 9992-7.
68. Johnson SM, Connelly S, Fearns C, Powers ET, Kelly JW., The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol 2012; 421: 185-203.
69. Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, et al., Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 2013; 310: 2658-67.